DE60017894T2 - Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen - Google Patents
Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen Download PDFInfo
- Publication number
- DE60017894T2 DE60017894T2 DE60017894T DE60017894T DE60017894T2 DE 60017894 T2 DE60017894 T2 DE 60017894T2 DE 60017894 T DE60017894 T DE 60017894T DE 60017894 T DE60017894 T DE 60017894T DE 60017894 T2 DE60017894 T2 DE 60017894T2
- Authority
- DE
- Germany
- Prior art keywords
- aryl
- amino
- heteroaryl
- alkyl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000001253 Protein Kinase Human genes 0.000 title claims description 32
- 108060006633 protein kinase Proteins 0.000 title claims description 32
- 230000005764 inhibitory process Effects 0.000 title description 13
- WKXCZMFWXZRMEZ-UHFFFAOYSA-N 1,3-thiazole-2,4-diamine Chemical compound NC1=CSC(N)=N1 WKXCZMFWXZRMEZ-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 150
- 125000003118 aryl group Chemical group 0.000 claims description 94
- 125000001072 heteroaryl group Chemical group 0.000 claims description 80
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 24
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 22
- 108091000080 Phosphotransferase Proteins 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 22
- 102000020233 phosphotransferase Human genes 0.000 claims description 22
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 230000033115 angiogenesis Effects 0.000 claims description 18
- 230000004663 cell proliferation Effects 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 208
- 238000005160 1H NMR spectroscopy Methods 0.000 description 174
- 238000004458 analytical method Methods 0.000 description 154
- -1 C 1 -C 8 -alkyl Chemical class 0.000 description 139
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
- 239000000243 solution Substances 0.000 description 97
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 68
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 57
- 235000019439 ethyl acetate Nutrition 0.000 description 48
- 239000002904 solvent Substances 0.000 description 46
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 41
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 39
- 238000012360 testing method Methods 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 32
- 238000005481 NMR spectroscopy Methods 0.000 description 30
- 239000000460 chlorine Substances 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 28
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 24
- 0 C*1CCCC1 Chemical compound C*1CCCC1 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 19
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- 239000012267 brine Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 15
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 13
- 108091007914 CDKs Proteins 0.000 description 12
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 12
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108091008794 FGF receptors Proteins 0.000 description 11
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 11
- 230000022131 cell cycle Effects 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 11
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 9
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 9
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 9
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 9
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 102000016736 Cyclin Human genes 0.000 description 8
- 108050006400 Cyclin Proteins 0.000 description 8
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 8
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 239000006184 cosolvent Substances 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 7
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 7
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 102000013009 Pyruvate Kinase Human genes 0.000 description 7
- 108020005115 Pyruvate Kinase Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- GRCMZHNTKLXDAP-UHFFFAOYSA-N COC1=C(OC)C(OC)=CC(C2(N)SC=C(N)N2)=C1 Chemical compound COC1=C(OC)C(OC)=CC(C2(N)SC=C(N)N2)=C1 GRCMZHNTKLXDAP-UHFFFAOYSA-N 0.000 description 6
- 108010068192 Cyclin A Proteins 0.000 description 6
- 102100025191 Cyclin-A2 Human genes 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 102000006313 Cyclin D3 Human genes 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000035578 autophosphorylation Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000003909 protein kinase inhibitor Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- KKFQIFLHVDGQIW-UHFFFAOYSA-N 3-cyano-n-[(2-methylpropan-2-yl)oxy]benzamide Chemical compound CC(C)(C)ONC(=O)C1=CC=CC(C#N)=C1 KKFQIFLHVDGQIW-UHFFFAOYSA-N 0.000 description 4
- HSZLBBZSPHXHDJ-UHFFFAOYSA-N 4-[(4-amino-5-cyano-1,3-thiazol-2-yl)amino]benzenesulfonamide Chemical compound S1C(C#N)=C(N)N=C1NC1=CC=C(S(N)(=O)=O)C=C1 HSZLBBZSPHXHDJ-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- DZTJUPMWMPDPIY-UHFFFAOYSA-N 5-[4-(3-aminophenyl)-1,3-thiazol-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(N)C=CC=2)=C1 DZTJUPMWMPDPIY-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 108010058545 Cyclin D3 Proteins 0.000 description 4
- 230000012746 DNA damage checkpoint Effects 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 4
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- HDSHZLZMDAJJQD-UHFFFAOYSA-N n-(3-acetylphenyl)-5-chlorothiophene-2-carboxamide Chemical compound CC(=O)C1=CC=CC(NC(=O)C=2SC(Cl)=CC=2)=C1 HDSHZLZMDAJJQD-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- QWPMAZSSDIEIAO-UHFFFAOYSA-N 3-[5-(chloromethyl)-1,2,4-oxadiazol-3-yl]-n-[(2-methylpropan-2-yl)oxy]benzamide Chemical compound CC(C)(C)ONC(=O)C1=CC=CC(C=2N=C(CCl)ON=2)=C1 QWPMAZSSDIEIAO-UHFFFAOYSA-N 0.000 description 3
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 3
- ZFOXYMYPSAEQEA-UHFFFAOYSA-N 4-amino-2-(4-sulfamoylanilino)-1,3-thiazole-5-carbothioamide Chemical compound NC1=C(C(=S)N)SC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 ZFOXYMYPSAEQEA-UHFFFAOYSA-N 0.000 description 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 101150012716 CDK1 gene Proteins 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 3
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 108050002653 Retinoblastoma protein Proteins 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 3
- 208000030428 polyarticular arthritis Diseases 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- ZVQXQPNJHRNGID-UHFFFAOYSA-N tetramethylsuccinonitrile Chemical compound N#CC(C)(C)C(C)(C)C#N ZVQXQPNJHRNGID-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000006459 vascular development Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- CKQHAYFOPRIUOM-UHFFFAOYSA-N 3'-Aminoacetophenone Chemical compound CC(=O)C1=CC=CC(N)=C1 CKQHAYFOPRIUOM-UHFFFAOYSA-N 0.000 description 2
- NMQCHSGVKUTKBH-UHFFFAOYSA-N 3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenol Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(O)C=CC=2)=C1 NMQCHSGVKUTKBH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- RPJMTTUATVKBMN-UHFFFAOYSA-N 4-[[4-amino-5-(4-phenyl-1,3-thiazol-2-yl)-1,3-thiazol-2-yl]amino]benzenesulfonamide Chemical compound S1C(C=2SC=C(N=2)C=2C=CC=CC=2)=C(N)N=C1NC1=CC=C(S(N)(=O)=O)C=C1 RPJMTTUATVKBMN-UHFFFAOYSA-N 0.000 description 2
- XPXLWEBNQPZCBC-UHFFFAOYSA-N 4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazole-5-carbonitrile Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C#N)=C1 XPXLWEBNQPZCBC-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- OMNHTTWQSSUZHO-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC(C)=C1O OMNHTTWQSSUZHO-UHFFFAOYSA-N 0.000 description 2
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- IMDUFDNFSJWYQT-UHFFFAOYSA-N 4-isothiocyanatobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(N=C=S)C=C1 IMDUFDNFSJWYQT-UHFFFAOYSA-N 0.000 description 2
- HRSFRTHRNQEVAS-UHFFFAOYSA-N 5-(6-bromopyridin-2-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(Br)C=CC=2)=C1 HRSFRTHRNQEVAS-UHFFFAOYSA-N 0.000 description 2
- GGVQPLOEDLGZCX-UHFFFAOYSA-N 5-[3-(3-aminophenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(N)C=CC=2)=C1 GGVQPLOEDLGZCX-UHFFFAOYSA-N 0.000 description 2
- MWUVKOQSEMZSMN-UHFFFAOYSA-N 5-[3-(5-amino-2-fluoro-4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound C1=C(N)C(OC)=CC(F)=C1C1=NOC(C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=N1 MWUVKOQSEMZSMN-UHFFFAOYSA-N 0.000 description 2
- XRTUGPXTPHQKFN-UHFFFAOYSA-N 5-[6-(furan-2-yl)pyridin-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(C=CC=2)C=2OC=CC=2)=C1 XRTUGPXTPHQKFN-UHFFFAOYSA-N 0.000 description 2
- FVHWIBHCJNCRAI-UHFFFAOYSA-N 5-chloro-n-[3-[2-(2,4-diamino-1,3-thiazol-5-yl)-1,3-thiazol-4-yl]phenyl]thiophene-2-carboxamide Chemical compound S1C(N)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3SC(Cl)=CC=3)C=CC=2)=CS1 FVHWIBHCJNCRAI-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241001136792 Alle Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100034594 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 101150050673 CHK1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- 102000002427 Cyclin B Human genes 0.000 description 2
- 108010068150 Cyclin B Proteins 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 108090000257 Cyclin E Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000715942 Homo sapiens Cyclin-dependent kinase 4 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 102000048992 human CDK4 Human genes 0.000 description 2
- 102000048620 human CHEK1 Human genes 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- JMJUHQGPXJPKRH-UHFFFAOYSA-N n-[3-(2-bromoacetyl)phenyl]-5-chlorothiophene-2-carboxamide Chemical compound S1C(Cl)=CC=C1C(=O)NC1=CC=CC(C(=O)CBr)=C1 JMJUHQGPXJPKRH-UHFFFAOYSA-N 0.000 description 2
- FZFIYOAPPGZOJL-UHFFFAOYSA-N n-[3-[2-(2,4-diamino-1,3-thiazol-5-yl)-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound S1C(N)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=CS1 FZFIYOAPPGZOJL-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 108010065665 syntide-2 Proteins 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- YNEUKTPESKGPNQ-VIFPVBQESA-N (1s)-1-amino-3-phenylpropan-1-ol Chemical compound N[C@@H](O)CCC1=CC=CC=C1 YNEUKTPESKGPNQ-VIFPVBQESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NKBRRWBNPNUBDD-TYKVATLISA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[2-[[(2s)-1-[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-4-methyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]pentanoyl]amino]propanoyl]amino]pentanoyl]amino]-3 Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)[C@@H](C)O)C(=O)[C@@H]1CCCN1 NKBRRWBNPNUBDD-TYKVATLISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LKUWQWDAIWXHIY-CHNJZELVSA-N (z)-2-methylbut-2-enoic acid Chemical compound C\C=C(\C)C(O)=O.C\C=C(\C)C(O)=O LKUWQWDAIWXHIY-CHNJZELVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical compound BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 1
- QHHHLHCCVDMOJI-UHFFFAOYSA-N 1,3-thiazol-4-amine Chemical class NC1=CSC=N1 QHHHLHCCVDMOJI-UHFFFAOYSA-N 0.000 description 1
- CGXJUBDTCAAXAY-UHFFFAOYSA-N 1-(3-aminophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC(N)=C1 CGXJUBDTCAAXAY-UHFFFAOYSA-N 0.000 description 1
- VRYWBMTXKFQBCA-UHFFFAOYSA-N 1-(benzenesulfonyl)piperidine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1CCCCC1 VRYWBMTXKFQBCA-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- QAHATWMAZYFBSC-UHFFFAOYSA-N 2-(5-chlorothiophen-2-yl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)S1 QAHATWMAZYFBSC-UHFFFAOYSA-N 0.000 description 1
- SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 description 1
- BWCCPOQIMGGGQX-UHFFFAOYSA-N 2-(chloromethyl)-4,6-dimethoxypyrimidine Chemical compound COC1=CC(OC)=NC(CCl)=N1 BWCCPOQIMGGGQX-UHFFFAOYSA-N 0.000 description 1
- AJKIAERFLWQLAM-UHFFFAOYSA-N 2-(chloromethyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole Chemical compound O1C(CCl)=NN=C1C1=CC=C(Cl)C=C1 AJKIAERFLWQLAM-UHFFFAOYSA-N 0.000 description 1
- WZEWEZMUYDNMCZ-UHFFFAOYSA-N 2-(chloromethyl)-6-methoxy-1h-benzimidazole Chemical compound COC1=CC=C2N=C(CCl)NC2=C1 WZEWEZMUYDNMCZ-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- DDEAEWMDOSXKBX-UHFFFAOYSA-N 2-(chloromethyl)quinoline Chemical compound C1=CC=CC2=NC(CCl)=CC=C21 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ORUAFPVWGWTAGD-UHFFFAOYSA-N 2-[3-[2-[4-amino-2-(3-methylanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound CC1=CC=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(C=CC=2)C=2C(=CC=CC=2)C(N)=O)=C1 ORUAFPVWGWTAGD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- VFMGOJUUTAPPDA-UHFFFAOYSA-N 2-ethyl-5-methylpyrazole-3-carboxylic acid Chemical compound CCN1N=C(C)C=C1C(O)=O VFMGOJUUTAPPDA-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- GCKYUSVGXDHLIA-UHFFFAOYSA-N 2-n-[4-(dimethylamino)phenyl]-5-(2h-tetrazol-5-yl)-1,3-thiazole-2,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1NC1=NC(N)=C(C2=NNN=N2)S1 GCKYUSVGXDHLIA-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- MAGGXASHVAMJCT-UHFFFAOYSA-N 3-(bromomethyl)-6,7-dimethoxy-1-methylquinoxalin-2-one Chemical compound N1=C(CBr)C(=O)N(C)C2=C1C=C(OC)C(OC)=C2 MAGGXASHVAMJCT-UHFFFAOYSA-N 0.000 description 1
- YSNKGJCEHOJIDK-UHFFFAOYSA-N 3-(chloromethyl)-1,2,4-oxadiazole Chemical compound ClCC=1N=CON=1 YSNKGJCEHOJIDK-UHFFFAOYSA-N 0.000 description 1
- FEXTXBAFBURKGS-UHFFFAOYSA-N 3-(chloromethyl)-5-methyl-1,2-oxazole Chemical compound CC1=CC(CCl)=NO1 FEXTXBAFBURKGS-UHFFFAOYSA-N 0.000 description 1
- KHJYOJVUQYWASE-UHFFFAOYSA-N 3-(chloromethyl)-5-thiophen-3-yl-1,2,4-oxadiazole Chemical compound ClCC1=NOC(C2=CSC=C2)=N1 KHJYOJVUQYWASE-UHFFFAOYSA-N 0.000 description 1
- RMFKWWDNIKWLNN-UHFFFAOYSA-N 3-amino-4-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2-[(2-methylpropan-2-yl)oxy]benzoic acid Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=C(OC(C)(C)C)C(C(O)=O)=CC=2)N)=C1 RMFKWWDNIKWLNN-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NUSXEDNPFNWFDQ-UHFFFAOYSA-N 3-chloro-2-(chloromethyl)-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CN=C(CCl)C(Cl)=C1 NUSXEDNPFNWFDQ-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- PUZFMDAJRJLNJN-UHFFFAOYSA-N 3-methyloctanamide Chemical compound CCCCCC(C)CC(N)=O PUZFMDAJRJLNJN-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UEJQTBKTWJQBRN-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-chlorophenyl)-1,3-thiazole Chemical compound ClCC1=CSC(C=2C=CC(Cl)=CC=2)=N1 UEJQTBKTWJQBRN-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NNMYRMGMVLMQAY-UHFFFAOYSA-N 4-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=N1 NNMYRMGMVLMQAY-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical class OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- YVFDOWOSUGHFLZ-UHFFFAOYSA-N 5-(4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2OC(C(C)N=2)C=2C=CC=CC=2)=C1 YVFDOWOSUGHFLZ-UHFFFAOYSA-N 0.000 description 1
- DDLQRIDMGNVKCJ-UHFFFAOYSA-N 5-(6-thiophen-2-ylpyridin-2-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(C=CC=2)C=2SC=CC=2)=C1 DDLQRIDMGNVKCJ-UHFFFAOYSA-N 0.000 description 1
- NAGJNOJBNXYWAP-UHFFFAOYSA-N 5-(6-thiophen-3-ylpyridin-2-yl)-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C(C=CC=2)C2=CSC=C2)=C1 NAGJNOJBNXYWAP-UHFFFAOYSA-N 0.000 description 1
- BJVYSQGEJHKTBW-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-chlorophenyl)-1,2,4-oxadiazole Chemical compound O1C(CCl)=NC(C=2C=CC(Cl)=CC=2)=N1 BJVYSQGEJHKTBW-UHFFFAOYSA-N 0.000 description 1
- RYZHGEZWUMHELK-UHFFFAOYSA-N 5-(chloromethyl)-3-(4-chlorophenyl)-1h-1,2,4-triazole Chemical compound N1C(CCl)=NN=C1C1=CC=C(Cl)C=C1 RYZHGEZWUMHELK-UHFFFAOYSA-N 0.000 description 1
- MFEGTJBBLPXXDT-UHFFFAOYSA-N 5-(chloromethyl)-3-(pyridin-2-ylsulfonylmethyl)-1,2,4-oxadiazole Chemical compound O1C(CCl)=NC(CS(=O)(=O)C=2N=CC=CC=2)=N1 MFEGTJBBLPXXDT-UHFFFAOYSA-N 0.000 description 1
- KVFQFCXDQVNXDP-AWEZNQCLSA-N 5-[(4r)-4-phenyl-4,5-dihydro-1,3-oxazol-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2OC[C@H](N=2)C=2C=CC=CC=2)=C1 KVFQFCXDQVNXDP-AWEZNQCLSA-N 0.000 description 1
- YVFDOWOSUGHFLZ-SJKOYZFVSA-N 5-[(4r,5s)-4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2O[C@H]([C@@H](C)N=2)C=2C=CC=CC=2)=C1 YVFDOWOSUGHFLZ-SJKOYZFVSA-N 0.000 description 1
- VPRXACKBZBROKZ-UHFFFAOYSA-N 5-[3-(5-amino-2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(N)C=2)F)=C1 VPRXACKBZBROKZ-UHFFFAOYSA-N 0.000 description 1
- JHQONXHAPLRSTD-UHFFFAOYSA-N 5-[3-[3-(methoxymethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COCOC1=CC=CC(C=2N=C(ON=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 JHQONXHAPLRSTD-UHFFFAOYSA-N 0.000 description 1
- KJFGXEAWTFOJJQ-UHFFFAOYSA-N 5-[4-(chloromethyl)-1,3-thiazol-2-yl]-1,2-oxazole Chemical compound ClCC1=CSC(C=2ON=CC=2)=N1 KJFGXEAWTFOJJQ-UHFFFAOYSA-N 0.000 description 1
- YVTQHZDUDUCGRD-UHFFFAOYSA-N 5-bromofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)O1 YVTQHZDUDUCGRD-UHFFFAOYSA-N 0.000 description 1
- FFFMIFUBJZBTCG-UHFFFAOYSA-N 5-chloro-3-(chloromethyl)-1,2,4-thiadiazole Chemical compound ClCC1=NSC(Cl)=N1 FFFMIFUBJZBTCG-UHFFFAOYSA-N 0.000 description 1
- DADXWROZAWLOFB-UHFFFAOYSA-N 5-chloro-4-(chloromethyl)thiadiazole Chemical compound ClCC=1N=NSC=1Cl DADXWROZAWLOFB-UHFFFAOYSA-N 0.000 description 1
- QZLSBOVWPHXCLT-UHFFFAOYSA-N 5-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)S1 QZLSBOVWPHXCLT-UHFFFAOYSA-N 0.000 description 1
- AFWKAIYTSPWWCA-UHFFFAOYSA-N 5-isothiocyanato-1,2,3-trimethoxybenzene Chemical compound COC1=CC(N=C=S)=CC(OC)=C1OC AFWKAIYTSPWWCA-UHFFFAOYSA-N 0.000 description 1
- FPSIJTQWAZLSIH-UHFFFAOYSA-N 5-pyridin-2-yl-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=CC=CC=2)=C1 FPSIJTQWAZLSIH-UHFFFAOYSA-N 0.000 description 1
- BXANGIZBUPAFHR-UHFFFAOYSA-N 5-quinolin-2-yl-2-n-(3,4,5-trimethoxyphenyl)-1,3-thiazole-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2N=C3C=CC=CC3=CC=2)=C1 BXANGIZBUPAFHR-UHFFFAOYSA-N 0.000 description 1
- AIVSLDAXUIRICJ-UHFFFAOYSA-N 5-tert-butyl-3-(chloromethyl)-1,2,4-oxadiazole Chemical compound CC(C)(C)C1=NC(CCl)=NO1 AIVSLDAXUIRICJ-UHFFFAOYSA-N 0.000 description 1
- ZKCAVUYFKJKMRI-UHFFFAOYSA-N 6-(chloromethyl)-2-propan-2-yl-1h-pyrimidin-4-one Chemical compound CC(C)C1=NC(=O)C=C(CCl)N1 ZKCAVUYFKJKMRI-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- DABLXYJWGJFYIK-UHFFFAOYSA-N 7-[(4-bromophenyl)-(8-hydroxy-6-oxo-3,4-dihydro-2H-pyrimido[2,1-b][1,3]thiazin-7-yl)methyl]-8-hydroxy-3,4-dihydro-2H-pyrimido[2,1-b][1,3]thiazin-6-one Chemical compound [O-]c1[nH+]c2SCCCn2c(=O)c1C(c1ccc(Br)cc1)c1c([O-])[nH+]c2SCCCn2c1=O DABLXYJWGJFYIK-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRVNKVGVGGVRNS-UHFFFAOYSA-N C1(=CC=CC=C1)C1(SC(=C(N1)N)C1=NC=CC=C1)N Chemical compound C1(=CC=CC=C1)C1(SC(=C(N1)N)C1=NC=CC=C1)N KRVNKVGVGGVRNS-UHFFFAOYSA-N 0.000 description 1
- LKQHEJXFYVIRJR-UHFFFAOYSA-N CC(C)CC(C(Nc1cc(-c2n[o]c(-c3c(N)nc(Nc4cccc(CN5CCCC5)c4)[s]3)n2)c(C)cc1)=O)O Chemical compound CC(C)CC(C(Nc1cc(-c2n[o]c(-c3c(N)nc(Nc4cccc(CN5CCCC5)c4)[s]3)n2)c(C)cc1)=O)O LKQHEJXFYVIRJR-UHFFFAOYSA-N 0.000 description 1
- QMLHQAUERFLEPA-UHFFFAOYSA-N CC(Nc1nc(NI)c(-c2nc(C(c3ccccc3)=O)c[s]2)[s]1)=O Chemical compound CC(Nc1nc(NI)c(-c2nc(C(c3ccccc3)=O)c[s]2)[s]1)=O QMLHQAUERFLEPA-UHFFFAOYSA-N 0.000 description 1
- KMNFEKQFQCRPKZ-YLHCSOALSA-N CCS/C(/c1c(N)nc(NC(NCCCN(CCC2)C2=O)=O)[s]1)=N\Cc(cc(c(F)c1)NC(c2cccc(OC)c2)=O)c1F Chemical compound CCS/C(/c1c(N)nc(NC(NCCCN(CCC2)C2=O)=O)[s]1)=N\Cc(cc(c(F)c1)NC(c2cccc(OC)c2)=O)c1F KMNFEKQFQCRPKZ-YLHCSOALSA-N 0.000 description 1
- 101150095530 CDS1 gene Proteins 0.000 description 1
- VUXDWHWOVWGCNH-UHFFFAOYSA-N COC(c1cc(C#N)ccc1)=[O]=C Chemical compound COC(c1cc(C#N)ccc1)=[O]=C VUXDWHWOVWGCNH-UHFFFAOYSA-N 0.000 description 1
- LFEFATYYLOGTCQ-HDJSIYSDSA-N COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)N[C@@H]4CC[C@@H](O)CC4)S3)N)C=2)F)=C1 Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)N[C@@H]4CC[C@@H](O)CC4)S3)N)C=2)F)=C1 LFEFATYYLOGTCQ-HDJSIYSDSA-N 0.000 description 1
- KYJJNJYPHIYGAN-UHFFFAOYSA-N COC=1C=C(C=CC1OC)C1(SC(=C(N1)N)C1=NC=CC=C1)N Chemical compound COC=1C=C(C=CC1OC)C1(SC(=C(N1)N)C1=NC=CC=C1)N KYJJNJYPHIYGAN-UHFFFAOYSA-N 0.000 description 1
- OSDDDVHKZLGKCR-QGZVFWFLSA-N COc1cc(C(Nc(cc(-c2c[s]c(C(SC(NC(NC[C@@H]3OCCC3)=O)=C)=C(N)N)n2)c(F)c2)c2F)=O)ccc1 Chemical compound COc1cc(C(Nc(cc(-c2c[s]c(C(SC(NC(NC[C@@H]3OCCC3)=O)=C)=C(N)N)n2)c(F)c2)c2F)=O)ccc1 OSDDDVHKZLGKCR-QGZVFWFLSA-N 0.000 description 1
- SBLUCPCQUZZCBW-UHFFFAOYSA-O COc1cccc(C(Nc(c([FH+])c2)cc(-c3n[o]c(C(SC(NC(NCc4cnccc4)=O)=CC4)=C4N)n3)c2F)=O)c1 Chemical compound COc1cccc(C(Nc(c([FH+])c2)cc(-c3n[o]c(C(SC(NC(NCc4cnccc4)=O)=CC4)=C4N)n3)c2F)=O)c1 SBLUCPCQUZZCBW-UHFFFAOYSA-O 0.000 description 1
- BECMJHBWAFBULI-INGKJJEOSA-N C\C=C(\C)C(=O)NC1=CC=C(C)C(C=2N=C(ON=2)C2=C(N=C(S2)C=2C=C(CN3CCCC3)C=CC=2)N)=C1 Chemical compound C\C=C(\C)C(=O)NC1=CC=C(C)C(C=2N=C(ON=2)C2=C(N=C(S2)C=2C=C(CN3CCCC3)C=CC=2)N)=C1 BECMJHBWAFBULI-INGKJJEOSA-N 0.000 description 1
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- RZOCTZOINVDOFN-UHFFFAOYSA-N Cc(c(-c1n[o]c(-c2c(N)nc(Nc(cc3OC)cc(OC)c3OC)[s]2)n1)c1)ccc1NC(c1cc(OC)ccc1)=O Chemical compound Cc(c(-c1n[o]c(-c2c(N)nc(Nc(cc3OC)cc(OC)c3OC)[s]2)n1)c1)ccc1NC(c1cc(OC)ccc1)=O RZOCTZOINVDOFN-UHFFFAOYSA-N 0.000 description 1
- JSRMOSONHGPNNO-UHFFFAOYSA-N Cc1c(Cc(cc2)ccc2F)[s]c(-c([s]c(Nc(cc2)ccc2S(N)(=O)=O)c2)c2N)n1 Chemical compound Cc1c(Cc(cc2)ccc2F)[s]c(-c([s]c(Nc(cc2)ccc2S(N)(=O)=O)c2)c2N)n1 JSRMOSONHGPNNO-UHFFFAOYSA-N 0.000 description 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- 108010060387 Cyclin B2 Proteins 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 1
- 102100033201 G2/mitotic-specific cyclin-B2 Human genes 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920001367 Merrifield resin Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LSYSKEPZWVDQBH-UHFFFAOYSA-N N-[3-[5-[4-amino-2-(4-hydroxyphenyl)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-2-ethyl-5-methylpyrazole-3-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1=CC=C(C)C(C=2N=C(ON=2)C2=C(N=C(S2)C=2C=CC(O)=CC=2)N)=C1 LSYSKEPZWVDQBH-UHFFFAOYSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- KYKPMNVLZRQRHZ-UHFFFAOYSA-N NNC(c1cc(C#N)ccc1)=O Chemical compound NNC(c1cc(C#N)ccc1)=O KYKPMNVLZRQRHZ-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- ADSFPZFZPFYLTN-UHFFFAOYSA-N O1CCOC2=C1C=CC(=C2)C2(SC(=C(N2)N)C2=NC=CC=C2)N Chemical compound O1CCOC2=C1C=CC(=C2)C2(SC(=C(N2)N)C2=NC=CC=C2)N ADSFPZFZPFYLTN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- MQQULUHXIZXXKK-UHFFFAOYSA-N S1C(=C2N=CCS2)C(N)=NC1(NC=1C=C2CCCC2=CC=1)NC(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 Chemical compound S1C(=C2N=CCS2)C(N)=NC1(NC=1C=C2CCCC2=CC=1)NC(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 MQQULUHXIZXXKK-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HFQXHJYCGUAHKE-QGZVFWFLSA-N [(1r)-1-phenylethyl] n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)O[C@H](C)C=3C=CC=CC=3)C=CC=2)=C1 HFQXHJYCGUAHKE-QGZVFWFLSA-N 0.000 description 1
- LAJYPBBEOOFMQD-UHFFFAOYSA-N [3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-fluorophenyl]-[(2-methylpropan-2-yl)oxy]carbamic acid Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(C=2)N(OC(C)(C)C)C(O)=O)F)=C1 LAJYPBBEOOFMQD-UHFFFAOYSA-N 0.000 description 1
- MYISTVMWZSRGAV-UHFFFAOYSA-N [3-[5-[4-amino-2-(tritylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]carbamic acid Chemical compound S1C(C=2ON=C(N=2)C=2C=C(NC(O)=O)C=CC=2)=C(N)N=C1NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 MYISTVMWZSRGAV-UHFFFAOYSA-N 0.000 description 1
- ISLYWOHNYAUCJV-UHFFFAOYSA-N [NH-]c1c(C(C2)=NOC2c2c[s]cc2)[s]c(Nc2cc(C=O)c(C(F)(F)F)c(C(F)(F)F)c2)c1 Chemical compound [NH-]c1c(C(C2)=NOC2c2c[s]cc2)[s]c(Nc2cc(C=O)c(C(F)(F)F)c(C(F)(F)F)c2)c1 ISLYWOHNYAUCJV-UHFFFAOYSA-N 0.000 description 1
- ZPZHAUXTGFNYTN-UHFFFAOYSA-N [isothiocyanato(diphenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N=C=S)C1=CC=CC=C1 ZPZHAUXTGFNYTN-UHFFFAOYSA-N 0.000 description 1
- WFECKZNWXDGJRC-UHFFFAOYSA-N acetaldehyde;methanol Chemical compound OC.CC=O WFECKZNWXDGJRC-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- MANVMTSCCSAYSN-UHFFFAOYSA-N acetonitrile;2-methylpropan-2-ol Chemical compound CC#N.CC(C)(C)O MANVMTSCCSAYSN-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- AFZRIWFYOZPJEB-UHFFFAOYSA-N benzyl n-[3-[2-[4-amino-2-(2,5-dimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound COC1=CC=C(OC)C(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)OCC=3C=CC=CC=3)C=CC=2)=C1 AFZRIWFYOZPJEB-UHFFFAOYSA-N 0.000 description 1
- NNLBOGPAQKODFA-UHFFFAOYSA-N benzyl n-[3-[2-[4-amino-2-(4-methylanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound C1=CC(C)=CC=C1NC1=NC(N)=C(C=2SC=C(N=2)C=2C=C(NC(=O)OCC=3C=CC=CC=3)C=CC=2)S1 NNLBOGPAQKODFA-UHFFFAOYSA-N 0.000 description 1
- CNXBZQYIWKKVCU-UHFFFAOYSA-N benzyl n-[3-[2-[4-amino-2-(4-phenoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound S1C(C=2SC=C(N=2)C=2C=C(NC(=O)OCC=3C=CC=CC=3)C=CC=2)=C(N)N=C1NC(C=C1)=CC=C1OC1=CC=CC=C1 CNXBZQYIWKKVCU-UHFFFAOYSA-N 0.000 description 1
- YWBUHTQWQACROE-UHFFFAOYSA-N benzyl n-[3-[2-[4-amino-2-(4-sulfamoylanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound S1C(C=2SC=C(N=2)C=2C=C(NC(=O)OCC=3C=CC=CC=3)C=CC=2)=C(N)N=C1NC1=CC=C(S(N)(=O)=O)C=C1 YWBUHTQWQACROE-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Chemical class 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 150000004777 chromones Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 201000000497 familial melanoma Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical class OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000055590 human KDR Human genes 0.000 description 1
- 102000057090 human PTK2 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- KZRAAPTWXAMZHQ-UHFFFAOYSA-N methoxymethanamine Chemical compound COCN KZRAAPTWXAMZHQ-UHFFFAOYSA-N 0.000 description 1
- VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 description 1
- GQEPZQFOQYCOKF-UHFFFAOYSA-N methyl 4-[[4-amino-5-[3-[2,4-difluoro-5-[(3-methoxybenzoyl)amino]phenyl]-1,2,4-oxadiazol-5-yl]-1,3-thiazol-2-yl]carbamoyloxy]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1OC(=O)NC1=NC(N)=C(C=2ON=C(N=2)C=2C(=CC(F)=C(NC(=O)C=3C=C(OC)C=CC=3)C=2)F)S1 GQEPZQFOQYCOKF-UHFFFAOYSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- PTLXYIUTZXJEPX-UHFFFAOYSA-N methyl n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound COC(=O)NC1=CC=CC(C=2N=C(SC=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 PTLXYIUTZXJEPX-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YTSCJNGLTOKOEQ-UHFFFAOYSA-N n-[3-(2-bromoacetyl)phenyl]benzamide Chemical compound BrCC(=O)C1=CC=CC(NC(=O)C=2C=CC=CC=2)=C1 YTSCJNGLTOKOEQ-UHFFFAOYSA-N 0.000 description 1
- MKZVBTMMFZRBIW-UHFFFAOYSA-N n-[3-[2-(2,4-diamino-1,3-thiazol-5-yl)-5-methyl-1,3-thiazol-4-yl]phenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C2=C(SC(=N2)C2=C(N=C(N)S2)N)C)=C1 MKZVBTMMFZRBIW-UHFFFAOYSA-N 0.000 description 1
- MTSZZDSMVJMYIV-UHFFFAOYSA-N n-[3-[2-[2-(3-acetamido-4-methylanilino)-4-amino-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound C1=C(C)C(NC(=O)C)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 MTSZZDSMVJMYIV-UHFFFAOYSA-N 0.000 description 1
- QSSIYKLZUGWETA-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(1,3-benzodioxol-5-ylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound NC=1N=C(NC=2C=C3OCOC3=CC=2)SC=1C(SC=1)=NC=1C(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 QSSIYKLZUGWETA-UHFFFAOYSA-N 0.000 description 1
- KNGHSLIEGYQZIC-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound NC=1N=C(NC=2C=C3OCCOC3=CC=2)SC=1C(SC=1)=NC=1C(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 KNGHSLIEGYQZIC-UHFFFAOYSA-N 0.000 description 1
- WEEWLOHTXTWMBE-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-1-benzofuran-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3OC4=CC=CC=C4C=3)C=CC=2)=C1 WEEWLOHTXTWMBE-UHFFFAOYSA-N 0.000 description 1
- RECUDXABVWRSIH-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-1-phenylmethanesulfonamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NS(=O)(=O)CC=3C=CC=CC=3)C=CC=2)=C1 RECUDXABVWRSIH-UHFFFAOYSA-N 0.000 description 1
- RNNLQXOACJGOEQ-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-2,4-dimethyl-1,3-thiazole-5-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C3=C(N=C(C)S3)C)C=CC=2)=C1 RNNLQXOACJGOEQ-UHFFFAOYSA-N 0.000 description 1
- GPACSGUBSCAYNZ-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-2-chloropyridine-4-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=C(Cl)N=CC=3)C=CC=2)=C1 GPACSGUBSCAYNZ-UHFFFAOYSA-N 0.000 description 1
- NOEYQHCHBZWEAL-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3SC(C)=NC=3)C=CC=2)=C1 NOEYQHCHBZWEAL-UHFFFAOYSA-N 0.000 description 1
- ACMPNTBUPQJOLE-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-2-phenoxyacetamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)COC=3C=CC=CC=3)C=CC=2)=C1 ACMPNTBUPQJOLE-UHFFFAOYSA-N 0.000 description 1
- VXORRZUGVAIDMF-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-2-phenylacetamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)CC=3C=CC=CC=3)C=CC=2)=C1 VXORRZUGVAIDMF-UHFFFAOYSA-N 0.000 description 1
- NKYKPOIMGPIVJP-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3,4-dimethylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=C(C)C(C)=CC=3)C=CC=2)=C1 NKYKPOIMGPIVJP-UHFFFAOYSA-N 0.000 description 1
- SDOSNFOBYVHUOW-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-bromobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=C(Br)C=CC=3)C=CC=2)=C1 SDOSNFOBYVHUOW-UHFFFAOYSA-N 0.000 description 1
- XYGBBKUGEILYIM-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-ethylbenzamide Chemical compound CCC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(SC=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 XYGBBKUGEILYIM-UHFFFAOYSA-N 0.000 description 1
- BDKRQDHDPJXTSS-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-methoxy-4-methylbenzamide Chemical compound C1=C(C)C(OC)=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(SC=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 BDKRQDHDPJXTSS-UHFFFAOYSA-N 0.000 description 1
- BIPFXUDYOGOIQB-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(SC=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 BIPFXUDYOGOIQB-UHFFFAOYSA-N 0.000 description 1
- MNJCFJATOHVKAY-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-methylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=C(C)C=CC=3)C=CC=2)=C1 MNJCFJATOHVKAY-UHFFFAOYSA-N 0.000 description 1
- SYJFMPRJVCCTJS-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-phenylpropanamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 SYJFMPRJVCCTJS-UHFFFAOYSA-N 0.000 description 1
- JZJGLOPZHBOVLL-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-propan-2-ylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=C(C=CC=3)C(C)C)C=CC=2)=C1 JZJGLOPZHBOVLL-UHFFFAOYSA-N 0.000 description 1
- MBUHTDKPYANDMP-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-4-fluorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=CC(F)=CC=3)C=CC=2)=C1 MBUHTDKPYANDMP-UHFFFAOYSA-N 0.000 description 1
- PNGBUVBURRKMQC-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-4-hydroxy-3,5-dimethylbenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=C(C)C(O)=C(C)C=3)C=CC=2)=C1 PNGBUVBURRKMQC-UHFFFAOYSA-N 0.000 description 1
- DBPOSXFTIBPOOI-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-5-bromothiophene-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3SC(Br)=CC=3)C=CC=2)=C1 DBPOSXFTIBPOOI-UHFFFAOYSA-N 0.000 description 1
- YKQKILMRTKIWFL-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-5-chlorothiophene-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3SC(Cl)=CC=3)C=CC=2)=C1 YKQKILMRTKIWFL-UHFFFAOYSA-N 0.000 description 1
- HREXKXJBTXYIBW-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-5-methyl-1,3-thiazole-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3SC(C)=CN=3)C=CC=2)=C1 HREXKXJBTXYIBW-UHFFFAOYSA-N 0.000 description 1
- QGUUYPAUOMBCQA-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-5-methylthiophene-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3SC(C)=CC=3)C=CC=2)=C1 QGUUYPAUOMBCQA-UHFFFAOYSA-N 0.000 description 1
- SSJXREZZBMQIFF-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-5-phenyl-1,3-oxazole-4-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C3=C(OC=N3)C=3C=CC=CC=3)C=CC=2)=C1 SSJXREZZBMQIFF-UHFFFAOYSA-N 0.000 description 1
- ZZRRBTYFFQMDKO-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-6-chloropyridine-2-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3N=C(Cl)C=CC=3)C=CC=2)=C1 ZZRRBTYFFQMDKO-UHFFFAOYSA-N 0.000 description 1
- DNAMWUDZCKOYPJ-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(C)=O)C=CC=2)=C1 DNAMWUDZCKOYPJ-UHFFFAOYSA-N 0.000 description 1
- VXQKUNCQIQRGIH-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 VXQKUNCQIQRGIH-UHFFFAOYSA-N 0.000 description 1
- OTZGTVSSOVXXSB-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]methanesulfonamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NS(C)(=O)=O)C=CC=2)=C1 OTZGTVSSOVXXSB-UHFFFAOYSA-N 0.000 description 1
- HZNZRQNEBPVFJE-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,4-dimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC(N)=C(C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)S1 HZNZRQNEBPVFJE-UHFFFAOYSA-N 0.000 description 1
- ZKMCTOQPLOEENW-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3,5-dimethylanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound CC1=CC(C)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 ZKMCTOQPLOEENW-UHFFFAOYSA-N 0.000 description 1
- XYYADYVAACEYQX-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(3-methylsulfanylanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound CSC1=CC=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 XYYADYVAACEYQX-UHFFFAOYSA-N 0.000 description 1
- VCKLFZGBHLVWHG-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=CS1 VCKLFZGBHLVWHG-UHFFFAOYSA-N 0.000 description 1
- RHYNKFINUMFRBE-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(OC)C=CC=3)C=CC=2)=CS1 RHYNKFINUMFRBE-UHFFFAOYSA-N 0.000 description 1
- DYVHSELRVGWZIC-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]-5-chlorothiophene-2-carboxamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3SC(Cl)=CC=3)C=CC=2)=CS1 DYVHSELRVGWZIC-UHFFFAOYSA-N 0.000 description 1
- DLYOTCXFOFMSLU-UHFFFAOYSA-N n-[3-[2-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-5-methyl-1,3-thiazol-4-yl]phenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(OC)C=CC=3)C=CC=2)=C(C)S1 DLYOTCXFOFMSLU-UHFFFAOYSA-N 0.000 description 1
- GBQNNAJCDBJEIZ-UHFFFAOYSA-N n-[3-[2-[4-amino-2-[(1,4-dioxo-2,3-dihydrophthalazin-6-yl)amino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound NC=1N=C(NC=2C=C3C(C(NNC3=O)=O)=CC=2)SC=1C(SC=1)=NC=1C(C=1)=CC=CC=1NC(=O)C1=CC=CC=C1 GBQNNAJCDBJEIZ-UHFFFAOYSA-N 0.000 description 1
- ZJDVINYEIRZFME-UHFFFAOYSA-N n-[3-[2-[4-amino-2-[3-(diethylamino)propylamino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]benzamide Chemical compound S1C(NCCCN(CC)CC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=CS1 ZJDVINYEIRZFME-UHFFFAOYSA-N 0.000 description 1
- RRAJZEHDJJVEPL-UHFFFAOYSA-N n-[3-[5-(2-acetamido-4-amino-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(NC(=O)C)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=NO1 RRAJZEHDJJVEPL-UHFFFAOYSA-N 0.000 description 1
- WNMGYLGYARZGMV-UHFFFAOYSA-N n-[3-[5-(4-amino-2-benzamido-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=C(N)N=C1NC(=O)C1=CC=CC=C1 WNMGYLGYARZGMV-UHFFFAOYSA-N 0.000 description 1
- ZHYBXLOWMPKRMI-UHFFFAOYSA-N n-[3-[5-(4-amino-2-phenyl-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-2-ethyl-5-methylpyrazole-3-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1=CC=C(C)C(C=2N=C(ON=2)C2=C(N=C(S2)C=2C=CC=CC=2)N)=C1 ZHYBXLOWMPKRMI-UHFFFAOYSA-N 0.000 description 1
- RGSPNONQAYJXTR-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-fluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C(F)=CC=2)C=2N=C(ON=2)C2=C(N=C(NC=3C=C(OC)C(OC)=C(OC)C=3)S2)N)=C1 RGSPNONQAYJXTR-UHFFFAOYSA-N 0.000 description 1
- LVVKMLFIYNWNIG-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(C)=O)C=CC=2)=C1 LVVKMLFIYNWNIG-UHFFFAOYSA-N 0.000 description 1
- QPGOMHQCTKAMIS-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]benzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 QPGOMHQCTKAMIS-UHFFFAOYSA-N 0.000 description 1
- HUSJGCHDRGJUGH-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3-amino-6-morpholin-4-ylpyridin-2-yl)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=C(C(C)=CC=2)C=2N=C(ON=2)C2=C(N=C(S2)C=2C(=CC=C(N=2)N2CCOCC2)N)N)=C1 HUSJGCHDRGJUGH-UHFFFAOYSA-N 0.000 description 1
- QRYVSMRZLRTCBB-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3-aminopyridin-2-yl)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound NC=1N=C(C=2C(=CC=CN=2)N)SC=1C(ON=1)=NC=1C(C=1)=CC=CC=1NC(=O)C1=CC=CC(Cl)=C1 QRYVSMRZLRTCBB-UHFFFAOYSA-N 0.000 description 1
- IABQUQFYGOHZOQ-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(3-morpholin-4-ylpropylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NC(=O)NCCCN3CCOCC3)S2)N)=C1 IABQUQFYGOHZOQ-UHFFFAOYSA-N 0.000 description 1
- OTVMTTXWIFYVMO-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(methanesulfonamido)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NS(C)(=O)=O)S2)N)=C1 OTVMTTXWIFYVMO-UHFFFAOYSA-N 0.000 description 1
- MGFZFZRURLWOFI-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(C)C=CC=3)C=CC=2)=NO1 MGFZFZRURLWOFI-UHFFFAOYSA-N 0.000 description 1
- IGSZJONBMJNESL-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(phenylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NC=2C=C(C=CC=2)C=2N=C(ON=2)C2=C(N=C(NC(=O)NC=3C=CC=CC=3)S2)N)=C1 IGSZJONBMJNESL-UHFFFAOYSA-N 0.000 description 1
- FNOSXKUFNBHRNB-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(propan-2-ylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-methylbenzamide Chemical compound S1C(NC(=O)NC(C)C)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(C)C=CC=3)C=CC=2)=NO1 FNOSXKUFNBHRNB-UHFFFAOYSA-N 0.000 description 1
- VJPGSGFDJPHBMZ-UHFFFAOYSA-N n-[3-[5-[4-amino-2-(propanoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]-3-chlorobenzamide Chemical compound S1C(NC(=O)CC)=NC(N)=C1C1=NC(C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=NO1 VJPGSGFDJPHBMZ-UHFFFAOYSA-N 0.000 description 1
- NBUKMHXINQOFDI-UHFFFAOYSA-N n-[4-(chloromethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(CCl)=CS1 NBUKMHXINQOFDI-UHFFFAOYSA-N 0.000 description 1
- MDEKZURPUUQKCB-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(1-methoxypropan-2-ylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)NC(C)COC)=NC(N)=C1C1=NC(C=2C(=CC(F)=C(NC(=O)C=3C=C(OC)C=CC=3)C=2)F)=CS1 MDEKZURPUUQKCB-UHFFFAOYSA-N 0.000 description 1
- ZUZCJTZHCRRLBC-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(2-morpholin-4-ylethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCCN4CCOCC4)S3)N)C=2)F)=C1 ZUZCJTZHCRRLBC-UHFFFAOYSA-N 0.000 description 1
- FQWDTYJLDCNRAM-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(2-pyridin-2-ylethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCCC=4N=CC=CC=4)S3)N)C=2)F)=C1 FQWDTYJLDCNRAM-UHFFFAOYSA-N 0.000 description 1
- LCLNQMFSSVEHKU-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(2-pyridin-3-ylethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCCC=4C=NC=CC=4)S3)N)C=2)F)=C1 LCLNQMFSSVEHKU-UHFFFAOYSA-N 0.000 description 1
- RGWQFZOQMYFREC-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(2-pyrrolidin-1-ylethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCCN4CCCC4)S3)N)C=2)F)=C1 RGWQFZOQMYFREC-UHFFFAOYSA-N 0.000 description 1
- OSQMQPAVVLXAKN-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(pyridin-2-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCC=4N=CC=CC=4)S3)N)C=2)F)=C1 OSQMQPAVVLXAKN-UHFFFAOYSA-N 0.000 description 1
- CIMVYCJBZDZKLS-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(pyridin-3-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCC=4C=NC=CC=4)S3)N)C=2)F)=C1 CIMVYCJBZDZKLS-UHFFFAOYSA-N 0.000 description 1
- LPQCQLYQPOZBMW-UHFFFAOYSA-N n-[5-[2-[4-amino-2-(pyridin-4-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCC=4C=CN=CC=4)S3)N)C=2)F)=C1 LPQCQLYQPOZBMW-UHFFFAOYSA-N 0.000 description 1
- MYFXYSADAMBVLB-UHFFFAOYSA-N n-[5-[2-[4-amino-2-[3-(2-oxopyrrolidin-1-yl)propylcarbamoylamino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NCCCN4C(CCC4)=O)S3)N)C=2)F)=C1 MYFXYSADAMBVLB-UHFFFAOYSA-N 0.000 description 1
- VVROKSONNNEAJE-CYBMUJFWSA-N n-[5-[2-[4-amino-2-[[(2r)-1-hydroxybutan-2-yl]carbamoylamino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)N[C@@H](CO)CC)=NC(N)=C1C1=NC(C=2C(=CC(F)=C(NC(=O)C=3C=C(OC)C=CC=3)C=2)F)=CS1 VVROKSONNNEAJE-CYBMUJFWSA-N 0.000 description 1
- BUDOLNBNMKDLOB-OAHLLOKOSA-N n-[5-[2-[4-amino-2-[[(2r)-oxolan-2-yl]methylcarbamoylamino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NC[C@@H]4OCCC4)S3)N)C=2)F)=C1 BUDOLNBNMKDLOB-OAHLLOKOSA-N 0.000 description 1
- VVROKSONNNEAJE-ZDUSSCGKSA-N n-[5-[2-[4-amino-2-[[(2s)-1-hydroxybutan-2-yl]carbamoylamino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)N[C@H](CO)CC)=NC(N)=C1C1=NC(C=2C(=CC(F)=C(NC(=O)C=3C=C(OC)C=CC=3)C=2)F)=CS1 VVROKSONNNEAJE-ZDUSSCGKSA-N 0.000 description 1
- WFVKBWWXHUFBLM-NSHDSACASA-N n-[5-[2-[4-amino-2-[[(2s)-2-hydroxypropyl]carbamoylamino]-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(SC=3)C3=C(N=C(NC(=O)NC[C@H](C)O)S3)N)C=2)F)=C1 WFVKBWWXHUFBLM-NSHDSACASA-N 0.000 description 1
- MKIDEHRKLAONRP-UHFFFAOYSA-N n-[5-[5-(2,4-diamino-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(N)S3)N)C=2)F)=C1 MKIDEHRKLAONRP-UHFFFAOYSA-N 0.000 description 1
- DEPLPDUTJUFQJP-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(2-methylpropylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC(C)C)S3)N)C=2)F)=C1 DEPLPDUTJUFQJP-UHFFFAOYSA-N 0.000 description 1
- GVQCMQZGPFPMNM-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(2-morpholin-4-ylethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCCN4CCOCC4)S3)N)C=2)F)=C1 GVQCMQZGPFPMNM-UHFFFAOYSA-N 0.000 description 1
- KAWXMUIAAFAASH-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-chlorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC(F)=C(NC(=O)C=3C=C(Cl)C=CC=3)C=2)F)=C1 KAWXMUIAAFAASH-UHFFFAOYSA-N 0.000 description 1
- HAPMXNDWLJTRSV-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-chloro-2-fluorophenyl]-3-chlorobenzamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC(F)=C(NC(=O)C=3C=C(Cl)C=CC=3)C=2)Cl)=C1 HAPMXNDWLJTRSV-UHFFFAOYSA-N 0.000 description 1
- GMCWEKMPBDFQHH-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(methylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound S1C(NC(=O)NC)=NC(N)=C1C1=NC(C=2C(=CC(F)=C(NC(=O)C=3C=C(OC)C=CC=3)C=2)F)=NO1 GMCWEKMPBDFQHH-UHFFFAOYSA-N 0.000 description 1
- QNOSFBYTDFISMM-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(oxolan-2-ylmethylcarbamoylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC4OCCC4)S3)N)C=2)F)=C1 QNOSFBYTDFISMM-UHFFFAOYSA-N 0.000 description 1
- GTVMEAWUBBAPTB-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(propan-2-ylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(C)C)S3)N)C=2)F)=C1 GTVMEAWUBBAPTB-UHFFFAOYSA-N 0.000 description 1
- UIYFQSSHCLOJLB-UHFFFAOYSA-N n-[5-[5-[4-amino-2-(pyridin-3-ylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC=4C=NC=CC=4)S3)N)C=2)F)=C1 UIYFQSSHCLOJLB-UHFFFAOYSA-N 0.000 description 1
- CJSQMWJIXUBAGG-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[(2-amino-2-oxoethyl)carbamoylamino]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCC(N)=O)S3)N)C=2)F)=C1 CJSQMWJIXUBAGG-UHFFFAOYSA-N 0.000 description 1
- PVRVVWDMIMCHHM-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[2-(2-hydroxyethoxy)ethylcarbamoylamino]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2,4-difluorophenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(F)=C(C=3N=C(ON=3)C3=C(N=C(NC(=O)NCCOCCO)S3)N)C=2)F)=C1 PVRVVWDMIMCHHM-UHFFFAOYSA-N 0.000 description 1
- FWVXNVVNMDZAMY-UHFFFAOYSA-N n-[5-[5-[4-amino-2-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-2-chloro-4-methylphenyl]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2C(=CC(C)=C(C=3N=C(ON=3)C3=C(N=C(S3)C=3C=NC(=CC=3)N3CCN(C)CC3)N)C=2)Cl)=C1 FWVXNVVNMDZAMY-UHFFFAOYSA-N 0.000 description 1
- LIWFOMKTUZTKPW-UHFFFAOYSA-N naphthalen-1-yl n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)OC=3C4=CC=CC=C4C=CC=3)C=CC=2)=C1 LIWFOMKTUZTKPW-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- GNWXVOQHLPBSSR-UHFFFAOYSA-N oxolane;toluene Chemical compound C1CCOC1.CC1=CC=CC=C1 GNWXVOQHLPBSSR-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- NNWYOQSDLLLRBL-UHFFFAOYSA-N phenyl n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)OC=3C=CC=CC=3)C=CC=2)=C1 NNWYOQSDLLLRBL-UHFFFAOYSA-N 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical class C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- JKVWXXUZHYDCAS-UHFFFAOYSA-N tert-butyl n-[3-[2-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2SC=C(N=2)C=2C=C(NC(=O)OC(C)(C)C)C=CC=2)=C1 JKVWXXUZHYDCAS-UHFFFAOYSA-N 0.000 description 1
- FNIZGUOAYHJTTJ-UHFFFAOYSA-N tert-butyl n-[3-[5-(2,4-diamino-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C=2N=C(ON=2)C2=C(N=C(N)S2)N)=C1 FNIZGUOAYHJTTJ-UHFFFAOYSA-N 0.000 description 1
- UNYJLAONEAKPOU-UHFFFAOYSA-N tert-butyl n-[3-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-chlorophenyl]carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC=C(NC(=O)OC(C)(C)C)C=2)Cl)=C1 UNYJLAONEAKPOU-UHFFFAOYSA-N 0.000 description 1
- GOCWSOWNTCCGCE-UHFFFAOYSA-N tert-butyl n-[3-[5-[4-amino-2-(tritylamino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C=2N=C(ON=2)C2=C(N=C(NC(C=3C=CC=CC=3)(C=3C=CC=CC=3)C=3C=CC=CC=3)S2)N)=C1 GOCWSOWNTCCGCE-UHFFFAOYSA-N 0.000 description 1
- SAYSNGJQQAPOFR-UHFFFAOYSA-N tert-butyl n-[3-[5-[4-amino-2-[3-(pyrrolidin-1-ylmethyl)phenyl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=C1C1=NOC(C2=C(N=C(S2)C=2C=C(CN3CCCC3)C=CC=2)N)=N1 SAYSNGJQQAPOFR-UHFFFAOYSA-N 0.000 description 1
- HNNRDZNSKMXALP-UHFFFAOYSA-N tert-butyl n-[5-[5-[4-amino-2-(3,4,5-trimethoxyanilino)-1,3-thiazol-5-yl]-1,2,4-oxadiazol-3-yl]-4-chloro-2-fluorophenyl]carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC=2SC(=C(N)N=2)C=2ON=C(N=2)C=2C(=CC(F)=C(NC(=O)OC(C)(C)C)C=2)Cl)=C1 HNNRDZNSKMXALP-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13781099P | 1999-06-04 | 1999-06-04 | |
| US137810P | 1999-06-04 | ||
| PCT/US2000/015188 WO2000075120A1 (en) | 1999-06-04 | 2000-06-02 | Diaminothiazoles and their use for inhibiting protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60017894D1 DE60017894D1 (de) | 2005-03-10 |
| DE60017894T2 true DE60017894T2 (de) | 2005-12-29 |
Family
ID=22479135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60017894T Expired - Fee Related DE60017894T2 (de) | 1999-06-04 | 2000-06-02 | Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6620828B2 (https=) |
| EP (1) | EP1181283B1 (https=) |
| JP (1) | JP2003501420A (https=) |
| KR (1) | KR20020015333A (https=) |
| CN (1) | CN1359380A (https=) |
| AP (1) | AP2001002341A0 (https=) |
| AT (1) | ATE288424T1 (https=) |
| AU (1) | AU778071B2 (https=) |
| BG (1) | BG106276A (https=) |
| BR (1) | BR0011585A (https=) |
| CA (1) | CA2371158A1 (https=) |
| CZ (1) | CZ20014213A3 (https=) |
| DE (1) | DE60017894T2 (https=) |
| EA (1) | EA200101268A1 (https=) |
| EE (1) | EE200100659A (https=) |
| ES (1) | ES2234628T3 (https=) |
| HR (1) | HRP20020008A2 (https=) |
| HU (1) | HUP0202897A3 (https=) |
| IL (1) | IL146094A0 (https=) |
| IS (1) | IS6183A (https=) |
| MA (1) | MA25530A1 (https=) |
| MX (1) | MXPA01012483A (https=) |
| NO (1) | NO20015045L (https=) |
| NZ (1) | NZ514881A (https=) |
| OA (1) | OA11959A (https=) |
| PE (1) | PE20010211A1 (https=) |
| PL (1) | PL352714A1 (https=) |
| SK (1) | SK17302001A3 (https=) |
| SV (1) | SV2002000096A (https=) |
| UA (1) | UA71971C2 (https=) |
| UY (1) | UY26190A1 (https=) |
| WO (1) | WO2000075120A1 (https=) |
| YU (1) | YU85601A (https=) |
| ZA (1) | ZA200108291B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020150921A1 (en) * | 1996-02-09 | 2002-10-17 | Francis Barany | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| PL342447A1 (en) * | 1997-10-27 | 2001-06-04 | Agouron Pharma | Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| WO2002050071A1 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| JP2005504014A (ja) * | 2001-06-08 | 2005-02-10 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法 |
| EP1467981A1 (en) * | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| US6818663B2 (en) * | 2002-05-17 | 2004-11-16 | Hoffmann-La Roches | Diaminothiazoles |
| MXPA05001277A (es) * | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| AU2003278600A1 (en) * | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| MXPA05008878A (es) * | 2003-02-21 | 2005-10-05 | Pfizer | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. |
| US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| WO2004092217A1 (en) * | 2003-04-17 | 2004-10-28 | Pfizer Inc. | Crystal structure of vegfrkd: ligand complexes and methods of use thereof |
| WO2005007091A2 (en) * | 2003-07-07 | 2005-01-27 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| EP1663204B1 (en) * | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| EP2060270A3 (en) * | 2003-10-16 | 2009-12-09 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| AU2005205201B2 (en) | 2004-01-12 | 2011-05-12 | Merck Serono Sa | Thiazole derivatives and use thereof |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
| AU2005271843A1 (en) * | 2004-07-12 | 2006-02-16 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors |
| WO2006125807A1 (en) | 2005-05-24 | 2006-11-30 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| CN101248054B (zh) * | 2005-05-24 | 2012-05-09 | 默克雪兰诺有限公司 | 噻唑衍生物及其应用 |
| EP1945632B1 (en) | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| AU2006336504C9 (en) * | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| AU2012244242B2 (en) * | 2005-12-28 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| WO2007084391A2 (en) * | 2006-01-18 | 2007-07-26 | Amgen Inc. | Thiazole compounds as protein kinase b ( pkb) inhibitors |
| CN101484433A (zh) * | 2006-02-15 | 2009-07-15 | 艾博特公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| JP2009526868A (ja) * | 2006-02-15 | 2009-07-23 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| RU2462246C2 (ru) | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| CN101501023A (zh) * | 2006-07-07 | 2009-08-05 | 贝林格尔.英格海姆国际有限公司 | 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途 |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| CA2692379A1 (en) * | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| US7919504B2 (en) * | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| EP2173728A2 (en) | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| EP2639224B1 (en) | 2007-12-07 | 2016-08-24 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
| WO2009076140A1 (en) * | 2007-12-13 | 2009-06-18 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
| PL2387395T3 (pl) | 2009-01-16 | 2015-03-31 | Rigel Pharmaceuticals Inc | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym |
| EP2492269A4 (en) * | 2009-10-19 | 2013-08-07 | Taisho Pharmaceutical Co Ltd | aminothiazole |
| WO2011117382A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Pyridyltriazoles |
| WO2011117381A1 (en) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| HRP20211752T1 (hr) | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2013112804A1 (en) | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| TW201350479A (zh) | 2012-04-26 | 2013-12-16 | Ono Pharmaceutical Co | Ｔｒｋ阻害化合物 |
| AU2014219855B2 (en) | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| JP6963896B2 (ja) | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法 |
| KR102497273B1 (ko) | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
| PT3221692T (pt) | 2014-11-18 | 2021-09-10 | Vertex Pharma | Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência |
| JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス，インコーポレーテッド | てんかんの治療方法 |
| WO2018052967A1 (en) * | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
| CN121443601A (zh) * | 2023-07-03 | 2026-01-30 | 英矽智能科技知识产权有限公司 | 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法 |
| CN116874442B (zh) * | 2023-07-27 | 2025-10-24 | 武汉呈瑞生物医药科技有限公司 | 一种有机化合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE273062C (de) | 1912-04-19 | 1914-04-20 | Deylen Sohn Firma | Vorrichtung zum Schränken von Plattenzündspänen |
| AU558132B2 (en) | 1981-05-27 | 1987-01-22 | Labatt Brewing Co. Ltd. | Malt sterilisation with hydrogen peroxide |
| EP0218728A1 (en) | 1985-04-03 | 1987-04-22 | Yamanouchi Pharmaceutical Co. Ltd. | Phenylene derivatives |
| SG64322A1 (en) * | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| JPH07505155A (ja) | 1992-03-24 | 1995-06-08 | メルク シヤープ エンド ドーム リミテツド | コレシストキニン及び／又はガストリン拮抗活性を有する３−ウレイド置換ベンゾジアゼピン−２−オン及び治療におけるその使用 |
| US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
| WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| DK0808312T3 (da) | 1995-02-02 | 2001-02-12 | Smithkline Beecham Plc | Indolderivater som 5-HT-receptorantagonist |
| US5710173A (en) | 1995-06-07 | 1998-01-20 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
| AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| US5705499A (en) | 1995-10-06 | 1998-01-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| AU2103097A (en) | 1996-03-15 | 1997-10-10 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| EP0816357B1 (en) | 1996-06-27 | 2002-01-09 | Pfizer Inc. | Substituted indazole derivatives |
| EA002113B1 (ru) | 1996-09-04 | 2001-12-24 | Пфайзер Инк. | Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно) |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| PL342447A1 (en) * | 1997-10-27 | 2001-06-04 | Agouron Pharma | Substituted 4-amino thiazol-2-yl compounds as inhibitors of cyclin-dependent kinases |
| IL135714A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| IL135900A0 (en) | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeuticaly active compounds |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| EP1087951B9 (en) * | 1998-06-18 | 2006-09-13 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| ATE255575T1 (de) | 1998-09-29 | 2003-12-15 | Wyeth Corp | Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren |
-
2000
- 2000-02-06 UA UA2001129215A patent/UA71971C2/uk unknown
- 2000-06-02 WO PCT/US2000/015188 patent/WO2000075120A1/en not_active Ceased
- 2000-06-02 EE EEP200100659A patent/EE200100659A/xx unknown
- 2000-06-02 CZ CZ20014213A patent/CZ20014213A3/cs unknown
- 2000-06-02 UY UY26190A patent/UY26190A1/es not_active Application Discontinuation
- 2000-06-02 CN CN00808440A patent/CN1359380A/zh active Pending
- 2000-06-02 DE DE60017894T patent/DE60017894T2/de not_active Expired - Fee Related
- 2000-06-02 OA OA1200100321A patent/OA11959A/en unknown
- 2000-06-02 BR BR0011585-1A patent/BR0011585A/pt not_active IP Right Cessation
- 2000-06-02 EA EA200101268A patent/EA200101268A1/ru unknown
- 2000-06-02 IL IL14609400A patent/IL146094A0/xx unknown
- 2000-06-02 AP APAP/P/2001/002341A patent/AP2001002341A0/en unknown
- 2000-06-02 EP EP00942660A patent/EP1181283B1/en not_active Expired - Lifetime
- 2000-06-02 HR HR20020008A patent/HRP20020008A2/hr not_active Application Discontinuation
- 2000-06-02 SV SV2000000096A patent/SV2002000096A/es unknown
- 2000-06-02 MX MXPA01012483A patent/MXPA01012483A/es not_active Application Discontinuation
- 2000-06-02 PL PL00352714A patent/PL352714A1/xx not_active Application Discontinuation
- 2000-06-02 HU HU0202897A patent/HUP0202897A3/hu unknown
- 2000-06-02 JP JP2001501601A patent/JP2003501420A/ja not_active Abandoned
- 2000-06-02 KR KR1020017015384A patent/KR20020015333A/ko not_active Withdrawn
- 2000-06-02 CA CA002371158A patent/CA2371158A1/en not_active Abandoned
- 2000-06-02 NZ NZ514881A patent/NZ514881A/en unknown
- 2000-06-02 YU YU85601A patent/YU85601A/sh unknown
- 2000-06-02 ES ES00942660T patent/ES2234628T3/es not_active Expired - Lifetime
- 2000-06-02 AU AU57254/00A patent/AU778071B2/en not_active Ceased
- 2000-06-02 PE PE2000000553A patent/PE20010211A1/es not_active Application Discontinuation
- 2000-06-02 AT AT00942660T patent/ATE288424T1/de not_active IP Right Cessation
- 2000-06-02 SK SK1730-2001A patent/SK17302001A3/sk unknown
-
2001
- 2001-02-15 US US09/783,584 patent/US6620828B2/en not_active Expired - Fee Related
- 2001-10-09 ZA ZA200108291A patent/ZA200108291B/xx unknown
- 2001-10-17 NO NO20015045A patent/NO20015045L/no not_active Application Discontinuation
- 2001-11-29 IS IS6183A patent/IS6183A/is unknown
-
2002
- 2002-01-02 MA MA26465A patent/MA25530A1/fr unknown
- 2002-01-03 BG BG106276A patent/BG106276A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60017894T2 (de) | Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen | |
| US6462069B2 (en) | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | |
| DE69835241T2 (de) | 4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen | |
| KR20170042790A (ko) | 글리코시다제 저해제 | |
| JP2004531513A (ja) | 治療剤としてのピラゾールピリミジン | |
| JPWO2006054652A1 (ja) | アミド化合物 | |
| JP2007500183A (ja) | ３，５−二置換インダゾール化合物、医薬組成物、および細胞増殖を仲介又は阻害する方法 | |
| CN103080086B (zh) | 抑制前列腺素d合成酶的哌啶化合物 | |
| US6566363B2 (en) | Pyrazole-thiazole compounds, pharmaceutical compositions containing them | |
| JP4995189B2 (ja) | 尿素誘導体、その製造方法、およびその使用 | |
| JP6025907B2 (ja) | 癌などの疾患を処置するためのチアゾール誘導体 | |
| DE102005005395A1 (de) | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel | |
| DE60110802T2 (de) | Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen | |
| US20040176431A1 (en) | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |